Prostate cancer is the most common neoplasm in older men, with a median age at diagnosis of 66 years. In older adults, a widely heterogeneous population regarding functional status and other domains, treatment decisions can be complex: when chronological age alone is used for decision-making, it can lead to undertreatment or overtreatment, with negative impact on outcomes such as survival and/or quality of life.
Management of prostate cancer is a rapidly evolving field, with multiple therapeutic options developed and approved in the last decade. However, in comparison to information on the treatment of younger men, data on efficacy and tolerability of newer treatments in older adults with prostate cancer are limited, including the impact of therapies in independent living, cognition and other relevant outcomes in older adults.
The aim of this Research Topic is to develop a comprehensive and critical review of the management of prostate cancer in older adults throughout its natural history, from localized to metastatic castration-resistant disease, in order to improve outcomes in this patient population. We welcome Original Research Articles, Review Articles and Systematic Reviews dealing with topics including:
-Treatment of prostate cancer in older adults (surgery, radiotherapy and medical treatment including: chemotherapy, androgen deprivation therapy, new hormonal treatments, targeted therapy, immunotherapy, radioligand therapy.
-Geriatric assessment and geriatric interventions in older adults with prostate cancer
-Healthcare delivery and quality of care in older adults with prostate cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Prostate cancer is the most common neoplasm in older men, with a median age at diagnosis of 66 years. In older adults, a widely heterogeneous population regarding functional status and other domains, treatment decisions can be complex: when chronological age alone is used for decision-making, it can lead to undertreatment or overtreatment, with negative impact on outcomes such as survival and/or quality of life.
Management of prostate cancer is a rapidly evolving field, with multiple therapeutic options developed and approved in the last decade. However, in comparison to information on the treatment of younger men, data on efficacy and tolerability of newer treatments in older adults with prostate cancer are limited, including the impact of therapies in independent living, cognition and other relevant outcomes in older adults.
The aim of this Research Topic is to develop a comprehensive and critical review of the management of prostate cancer in older adults throughout its natural history, from localized to metastatic castration-resistant disease, in order to improve outcomes in this patient population. We welcome Original Research Articles, Review Articles and Systematic Reviews dealing with topics including:
-Treatment of prostate cancer in older adults (surgery, radiotherapy and medical treatment including: chemotherapy, androgen deprivation therapy, new hormonal treatments, targeted therapy, immunotherapy, radioligand therapy.
-Geriatric assessment and geriatric interventions in older adults with prostate cancer
-Healthcare delivery and quality of care in older adults with prostate cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
